You just read:

BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California

News provided by

BrainStorm Cell Therapeutics Inc.

07 Feb, 2018, 11:12 GMT